Search results
Showing 8491 to 8505 of 8853 results
Discontinued Reference number: GID-TAG410
Discontinued Reference number: GID-TA10353
Palforzia for treating peanut allergy in children and young people (TA769)
NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.
In development Reference number: GID-TA11586 Expected publication date: TBC
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]
Discontinued Reference number: GID-TA10199
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development Reference number: GID-HST10037 Expected publication date: TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development Reference number: GID-MT567 Expected publication date: TBC
In development Reference number: GID-TA11844 Expected publication date: TBC
In development Reference number: GID-TA11760 Expected publication date: TBC
Discontinued Reference number: GID-NG10300
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
This guidance has been replaced by NICE guideline NG17.
Major changes to type 2 diabetes treatment could save thousands of lives
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.